These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33724861)

  • 1. Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.
    Hu L; Mao X; Gao C; Xu Y; Li C; Wang T; Lv D
    Neoplasma; 2021 May; 68(3):638-644. PubMed ID: 33724861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
    Tibaldi C; Giovannetti E; Tiseo M; Leon LG; D'Incecco A; Loosekoot N; Bartolotti M; Honeywell R; Cappuzzo F; Ardizzoni A; Peters GJ
    Ann Oncol; 2012 Mar; 23(3):670-677. PubMed ID: 21652582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
    Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
    Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
    Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
    Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
    Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
    Li H; Wang X; Wang X
    Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
    Ding X; Chen W; Fan H; Zhu B
    Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
    Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
    Tibaldi C; Camerini A; Tiseo M; Mazzoni F; Barbieri F; Vittimberga I; Brighenti M; Boni L; Baldini E; Gilli A; Honeywell R; Chartoire M; Peters GJ; Giovannetti E;
    Br J Cancer; 2018 Nov; 119(11):1326-1331. PubMed ID: 30405211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
    Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
    Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
    Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
    Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
    Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
    Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
    Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
    Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.